Dr. Vande Woude received his M.S. (1962) and Ph.D. (1964) from Rutgers University. From 1964–1972, he served first as a postdoctoral research associate, then as a research virologist for the U.S. Department of Agriculture at Plum Island Animal Disease Center. In 1972, he joined the National Cancer Institute as Head of the Human Tumor Studies and Virus Tumor Biochemistry sections and, in 1980, was appointed Chief of the Laboratory of Molecular Oncology. In 1983, he became Director of the Advanced Bioscience Laboratories–Basic Research Program at the National Cancer Institute’s Frederick Cancer Research and Development Center, a position he held until 1998. From 1995, Dr. Vande Woude first served as Special Advisor to the Director, and then as Director for the Division of Basic Sciences at the National Cancer Institute. In 1999, he was recruited to the Directorship of Van Andel Research Institute in Grand Rapids, Michigan. In 2009, Vande Woude stepped down as Director and assumed the new title of Distinguished Scientific Fellow, as well as retaining his role of head of the Laboratory of Molecular Oncology.

Knudsen, B.S., and G. Vande Woude. 2008. Showering c-Met dependent cancers with drugs. Curr. Opinion Genet. Develop. 18(1): 87-96.  PubMed   Article  

Rouleau, C., K. Menon, P. Boutin, C. Guyre, H. Yoshida, S. Kataoka, M. Perricone, S. Shankara, A.E. Frankel, N.S. Duesbery, G.F. Vande Woude, H.-P. Biemann, and B.A. Teicher. 2008. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. International Journal Oncology 32(4): 739–748.  PubMed   Article  

Zhao, P., T. Grabinski, C. Gao, R.S. Skinner, T. Giambernardi, Y. Su, E. Hudson, J. Resau, M. Gross, G.F. Vande Woude, R. Hay, and B. Cao. 2007. Identification of a Met-binding peptide from a phage display library. Clin. Cancer Res. 13(20): 6049-6055.  PubMed   Article  

Tolbert, W.D., J. Daugherty, C. Gao, Q. Xie, C. Miranti, E. Gherardi, G. Vande Woude, and H.E. Xu. 2007. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proceedings of the National Academy of Sciences U.S.A. 104(37): 14592-14597.  PubMed   Article  

Lindemann, K., J. Resau, J. Nährig, E. Kort, B. Leeser, K. Anneke, A. Welk, J. Schäfer, G.F. Vande Woude, E. Lengyel, and N. Harbeck. 2007. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 51(1): 54–62.  PubMed   Article  

Gao, C., K. Furge, J. Koeman, K. Dykema, Y. Su, M.L. Cutler, A. Werts, P. Haak, and G.F. Vande Woude. 2007. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc. Natl. Acad. Sci. U.S.A. 104(21): 8995-9000.  PubMed   Article  

Zhang, Y.-W., and G.F. Vande Woude. 2007. Mig-6, signal transduction, stress response and cancer. Cell Cycle 6(5): 507–513.  PubMed   Article  

Moshitch-Moshkovitz, S., G. Tsarfaty, D.W. Kaufman, G.Y. Stein, K. Shichrur, E. Solomon, R.H. Sigler, J.H. Resau, G.F. Vande Woude, and I. Tsarfaty. 2006. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia 8(5): 353–363.  PubMed   Article  

Tsarfaty, G., G.Y. Stein, S. Moshitch-Moshkovitz, D.W. Kaufman, B. Cao, J.H. Resau, G.F. Vande Woude, and I. Tsarfaty. 2006. HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia 8(5): 344-52.  PubMed   Article  

Duesbery, Nick, and George Vande Woude. 2006. BRAF and MEK mutations make a late entrance. Science’s STKE 328: pe15.  PubMed   Article  

Orchekowski, R., D. Hamelinck, L. Li, E. Gliwa, M. VanBrocklin, J.A. Marrero, G.F. Vande Woude, Z. Feng, R. Brand, and B.B. Haab. 2005. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Research 65(23): 11193–11202.  PubMed   Article  

Hay, Rick V., Brian Cao, R. Scot Skinner, Yanli Su, Ping Zhao, Margaret F. Gustafson, Chao-Nan Qian, Bin T. Teh, Beatrice S. Knudsen, James H. Resau, Shuren Shen, David J. Waters, Milton D. Gross, and George F. Vande Woude. 2005. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek™). Clinical Cancer Research 11(19): 7064s–7069s.  PubMed   Article  

Ren, Yi, Brian Cao, Simon Law, Yi Xie, Ping Yin Lee, Leo Cheung, Yongxong Chen, Xin Huang, Hiu Man Chan, Ping Zhao, John Luk, George Vande Woude, and John Wong. 2005. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clinical Cancer Research 11(17): 6190–6197.  PubMed   Article  

Zhang, Yu-Wen, Yanli Su, Nathan Lanning, Pamela J. Swiatek, Roderick T. Bronson, Robert Sigler, Richard W. Martin, and George F. Vande Woude. 2005. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proceedings of the National Academy of Sciences U.S.A 102(33): 11740–11745.  PubMed   Article  

Gao, C-F., Xie, Q., Su, Y-L., Koeman, J., Khoo, S.K., Gustafson, M., Knudsen, B.S., Hay, R., Shinomiya, N., and Vande Woude, G.F. 2005. Proliferation and invasion: plasticity in tumor cells. Proceedings of the National Academy of Science of the United states of America 102(30): 10528–10533.  PubMed   Article  

Shen, Yuehai, Qian Xie, Monica Norberg, Edward Sausville, George F. Vande Woude, and David Wenkert. 2005. Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor–dependent urokinase-plasminogen activation. Bioorganic & Medicinal Chemistry 13(16): 4960–4971.  PubMed   Article  

Xie, Qian, Chong-Feng Gao, Nariyoshi Shinomiya, Edward Sausville, Rick Hay, Margaret Gustafson, Yuehai Shen, David Wenkert, and George F. Vande Woude. 2005. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24(23): 3697–3707.  PubMed   Article  

Graveel, Carrie R., Cheryl A. London, and George F. Vande Woude. 2005. A mouse model of activating Met mutations. Cell Cycle 4(4): 518–520.  PubMed   Article